Amydis Inc.

About Amydis Inc.

Amydis is a leader in developing ocular tracers for the digital detection and monitoring of disease-related molecular biomarkers using standard ocular imaging cameras. Their technology aims to accelerate diagnosis, enhance clinical testing of novel therapeutics, and revolutionize treatment for diseases of the eye, heart, and brain.

Products & Services

Ocular Tracers:A new class of tracers enabling digital detection and monitoring of human disease-related molecular biomarkers through ocular imaging cameras.

Specialties

Ocular Biomarkers Digital Detection Technology Precision Healthcare ALS Screening Transthyretin Amyloidosis Detection

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 3400000 MR: - FA: $3.4 million FAN: 3400000	D: 2023-11-14 FD: 2023-11-14	1 investors

Grant Latest

2023-11-14

$3.4M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Stella Sarraf

Chief Executive Officer

A

Ali Tafreshi

Chief Technology Advisor

K

Kerri Nelson

Chief Operating Officer

V

Vicki P. Raeburn

Chief Data Science Officer

A

Alex Huang

Chief Medical Advisor

R

Robert Weinreb, MD

Chair and Distinguished Professor of Ophthalmology

View 18 more team members with Pro

Unlock Full Team Directory

Recent News

Amydis Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised